Molecular targeted therapies for rhabdomyosarcoma: Focus on hedgehog and apoptosis signaling

Klinische Padiatrie

Volumn 225, Issue 3, 2013, Pages 115-119

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

apoptosis; Bcl 2; hedgehog; rhabdomyosarcoma; TRAIL

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 8; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN PATCHED 1; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

APOPTOSIS; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HETEROZYGOSITY LOSS; HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN GENE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATCHED 1 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TUMOR GENE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHILD; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84878422635     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0032-1331762     Document Type: Review

References (71)

1. Adams J. M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene: 2007; 26 1324 1337 (Pubitemid 46328466)
2. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov: 2008; 7 1001 1012
3. Barr F. G., Qualman S. J., Macris M. H. et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res: 2002; 62 4704 4710
4. Barti-Juhasz H., Mihalik R., Nagy K. et al. Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro. Haematologica: 2011; 96 e21 e22
5. Basit F., Humphreys R., Fulda S. RIP1 Protein-dependent Assembly of a Cytosolic Cell Death Complex Is Required for Inhibitor of Apoptosis (IAP) Inhibitor-mediated Sensitization to Lexatumumab-induced Apoptosis. J Biol Chem: 2012; 287 38767 38777
6. Beauchamp E. M., Ringer L., Bulut G. et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest: 2011; 121 148 160
7. Berman D. M., Karhadkar S. S., Hallahan A. R. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science: 2002; 297 1559 1561 (Pubitemid 34971004)
8. Berman D. M., Karhadkar S. S., Maitra A. et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature: 2003; 425 846 851 (Pubitemid 37351469)
9. Bigelow R. L., Chari N. S., Unden A. B. et al. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem: 2004; 279 1197 1205 (Pubitemid 38082643)
10. Bijlsma M. F., Spek C. A., Zivkovic D. et al. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol: 2006; 4 e232
11. Bridge J. A., Liu J., Qualman S. J. et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer: 2002; 33 310 321 (Pubitemid 34130938)
12. Calzada-Wack J., Kappler R., Schnitzbauer U. et al. Unbalanced overexpression of the mutant allele in murine Patched mutants. Carcinogenesis: 2002; 23 727 733 (Pubitemid 34567510)
13. Canettieri G., Di Marcotullio L., Greco A. et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol: 2010; 12 132 142
14. Cheong H. J., Lee K. S., Woo I. S. et al. Up-regulation of the DR5 expression by proteasome inhibitor MG132 augments TRAIL-induced apoptosis in soft tissue sarcoma cell lines. Cancer Res Treat: 2011; 43 124 130
15. Dagher R., Helman L. Rhabdomyosarcoma: an overview. Oncologist: 1999; 4 34 44 (Pubitemid 29102453)
16. Dantonello T. M., Int-Veen C., Harms D. et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol: 2009; 27 1446 1455
17. Ecke I., Rosenberger A., Obenauer S. et al. Cyclopamine treatment of full-blown Hh/Ptch-associated RMS partially inhibits Hh/Ptch signaling, but not tumor growth. Mol Carcinog: 2008; 47 361 372 (Pubitemid 351614576)
18. Ecke I., Petry F., Rosenberger A. et al. Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res: 2009; 69 887 895
19. Eichenmuller M., Hemmerlein B., von Schweinitz D. et al. Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. Br J Cancer: 2010; 103 43 51
20. Frühwald M. C., Witt O. The epigenetics of cancer in children. Klin Padiatr: 2008; 220 333 341
21. Fulda S., Kufer M. U., Meyer E. et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene: 2001; 20 5865 5877 (Pubitemid 32937956)
22. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett: 2009; 281 128 133
23. Fulda S., Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today: 2009; 14 885 890
24. Fulda S. Cell death and survival signaling in oncogenesis. Klin Padiatr: 2010; 222 340 344
25. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov: 2010; 9 447 464
26. Gorlin R. J. Nevoid basal cell carcinoma (Gorlin) syndrome: unanswered issues. J Lab Clin Med: 1999; 134 551 552
27. Hahn H., Wojnowski L., Zimmer A. M. et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med: 1998; 4 619 622 (Pubitemid 28237364)
28. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell: 2000; 100 57 70 (Pubitemid 30046295)
29. Hatton B. A., Knoepfler P. S., Kenney A. M. et al. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res: 2006; 66 8655 8661 (Pubitemid 44449181)
30. Hayes-Jordan A., Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr: 2009; 21 373 378
31. Hooper J. E., Scott M. P. Communicating with Hedgehogs. Nat Rev Mol Cell Biol: 2005; 6 306 317 (Pubitemid 40516897)
32. Kang Z., Chen J. J., Yu Y. et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res: 2011; 17 3181 3192
33. Kappler R., Calzada-Wack J., Schnitzbauer U. et al. Molecular characterization of Patched-associated rhabdomyosarcoma. J Pathol: 2003; 200 348 356 (Pubitemid 36827309)
34. Karhadkar S. S., Bova G. S., Abdallah N. et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature: 2004; 431 707 712 (Pubitemid 39382619)
35. Kasperczyk H., Baumann B., Debatin K. M. et al. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J: 2009; 23 21 33
36. Kawabata N., Ijiri K., Ishidou Y. et al. Pharmacological inhibition of the Hedgehog pathway prevents human rhabdomyosarcoma cell growth. Int J Oncol: 2011; 39 899 906
37. Khatib Z. A., Matsushime H., Valentine M. et al. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res: 1993; 53 5535 5541 (Pubitemid 23342180)
38. Kim J., Lee J. J., Gardner D. et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA: 2010; 107 13432 13437
39. Komdeur R., Meijer C., Van Zweeden M. et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol: 2004; 25 677 684
40. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev: 2007; 87 99 163 (Pubitemid 46209992)
41. Kuci S., Rettinger E., Voss B. et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica: 2010; 95 1579 1586
42. Lock R., Carol H., Houghton P. J. et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer: 2008; 50 1181 1189 (Pubitemid 351555542)
43. Low J. A., de Sauvage F. J. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol: 2010; 28 5321 5326
44. Margue C. M., Bernasconi M., Barr F. G. et al. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene: 2000; 19 2921 2929 (Pubitemid 30389082)
45. McPake C. R., Tillman D. M., Poquette C. A. et al. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. Oncology research: 1998; 10 235 244 (Pubitemid 128736319)
46. Merlino G., Helman L. J. Rhabdomyosarcoma - working out the pathways. Oncogene: 1999; 18 5340 5348 (Pubitemid 29462370)
47. Oltersdorf T., Elmore S. W., Shoemaker A. R. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature: 2005; 435 677 681 (Pubitemid 40825512)
48. Oue T., Yoneda A., Uehara S. et al. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg: 2010; 45 387 392
49. Pasca di Magliano M., Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer: 2003; 3 903 911 (Pubitemid 37500175)
50. Pazzaglia L., Chiechi A., Conti A. et al. Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes. Histol Histopathol: 2009; 24 61 67
51. Phillips D. C., Martin S., Doyle B. T. et al. Sphingosine-induced apoptosis in rhabdomyosarcoma cell lines is dependent on pre-mitochondrial Bax activation and post-mitochondrial caspases. Cancer Res: 2007; 67 756 764 (Pubitemid 46192216)
52. Pressey J. G., Anderson J. R., Crossman D. K. et al. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer: 2011; 57 930 938
53. Ragazzini P., Gamberi G., Pazzaglia L. et al. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol Histopathol: 2004; 19 401 411 (Pubitemid 38443902)
54. Ramirez-Peinado S., Alcazar-Limones F., Lagares-Tena L. et al. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res: 2011; 71 6796 6806
55. Riobo N. A., Lu K., Ai X. et al. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA: 2006; 103 4505 4510
56. Roberts W. M., Douglass E. C., Peiper S. C. et al. Amplification of the gli gene in childhood sarcomas. Cancer Res: 1989; 49 5407 5413 (Pubitemid 19240482)
57. Romer J. T., Kimura H., Magdaleno S. et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell: 2004; 6 229 240 (Pubitemid 39222036)
58. Rubin L. L., de Sauvage F. J. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov: 2006; 5 1026 1033 (Pubitemid 44835129)
59. Rudin C. M., Hann C. L., Laterra J. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med: 2009; 361 1173 1178
60. Scales S. J., de Sauvage F. J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci: 2009; 30 303 312
61. Sorensen P. H., Lynch J. C., Qualman S. J. et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol: 2002; 20 2672 2679 (Pubitemid 34575640)
62. Stecca B., Mas C., Clement V. et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA: 2007; 104 5895 5900 (Pubitemid 47175630)
63. Thayer S. P., di Magliano M. P., Heiser P. W. et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature: 2003; 425 851 856 (Pubitemid 37355945)
64. Tomek S., Koestler W., Horak P. et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer: 2003; 39 1318 1329 (Pubitemid 36579206)
65. Tostar U., Malm C. J., Meis-Kindblom J. M. et al. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol: 2006; 208 17 25 (Pubitemid 43025700)
66. Uhmann A., Niemann H., Lammering B. et al. Calcitriol inhibits hedgehog signaling and induces vitamin d receptor signaling and differentiation in the patched mouse model of embryonal rhabdomyosarcoma. Sarcoma: 2012; 2012 357040
67. Von Hoff D. D., LoRusso P. M., Rudin C. M. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med: 2009; 361 1164 1172
68. Watkins D. N., Berman D. M., Burkholder S. G. et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature: 2003; 422 313 317 (Pubitemid 36378358)
69. Wei C. C., Ball S., Lin L. et al. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells. Int J Oncol: 2011; 38 279 285
70. Williamson D., Missiaglia E., de Reynies A. et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol: 2010; 28 2151 2158
71. Zibat A., Missiaglia E., Rosenberger A. et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene: 2010; 29 6323 6330